Literature DB >> 12460192

Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.

Kwang-Mi Kim1, Ho Won Kim, Jae-Ouk Kim, Kyoung-Min Baek, Joong Gon Kim, Chang-Yuil Kang.   

Abstract

4-1BB(CD137) is a member of the tumour necrosis factor receptor superfamily and is expressed on activated T cells, monocytes and natural killer (NK) cells. The interaction of 4-1BB and 4-1BB ligand provides a costimulatory signal leading to T-cell activation. The expression of 4-1BB has been known to be activation dependent. Interestingly, we found that expression of 4-1BB increased in human peripheral blood mononuclear cells after exposure to mitomycin C. Thus, we tested whether the treatment with other DNA-damaging agents, such as doxorubicin, bleomycin, and gamma-irradiation, could induce 4-1BB expression. The data indicated that 4-1BB expression increased dose-dependently by these agents reaching maximum at 2-3 days after the exposure. We found that the major 4-1BB-expressing population was CD3+ T cells, although a moderate number of CD14+ cells and a few NKB1+ cells also expressed 4-1BB. The levels of 4-1BB expression induced by anticancer drugs, were relatively lower than that induced by CD3 ligation. Interestingly, at subcytotoxic concentrations, doxorubicin and bleomycin considerably enhanced 4-1BB expression induced by CD3 ligation in CEM cells. The ligation of the damage-induced 4-1BB by monoclonal antibody enhanced the viability and proliferating capacity of the cells. In conclusion, the expression of 4-1BB might be one of the cellular responses of the immune cells against various genotoxic stresses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460192      PMCID: PMC1782822          DOI: 10.1046/j.1365-2567.2002.01538.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  54 in total

1.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

2.  Isolation and initial characterization of multiple species of T-lymphocyte subset cDNA clones.

Authors:  B S Kwon; G S Kim; M B Prystowsky; D W Lancki; D E Sabath; J L Pan; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

3.  Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.

Authors:  L Gorelik; M Rubin; A Prokhorova; M B Mokyr
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

4.  Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.

Authors:  Toshiro Futagawa; Hisaya Akiba; Tomohiro Kodama; Kazuyoshi Takeda; Yasuyuki Hosoda; Hideo Yagita; Ko Okumura
Journal:  Int Immunol       Date:  2002-03       Impact factor: 4.823

5.  Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4.

Authors:  K E Pollok; S H Kim; B S Kwon
Journal:  Eur J Immunol       Date:  1995-02       Impact factor: 5.532

6.  Expression of cytokine mRNA in human melanoma tissues.

Authors:  E C Lattime; M J Mastrangelo; O Bagasra; W Li; D Berd
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

7.  ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages.

Authors:  H Schwarz; J Valbracht; J Tuckwell; J von Kempis; M Lotz
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

8.  Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma.

Authors:  D M Sahasrabudhe; J B deKernion; J E Pontes; D M Ryan; R W O'Donnell; D M Marquis; G S Mudholkar; C S McCune
Journal:  J Biol Response Mod       Date:  1986-12

9.  Bleomycin clinical pharmacology by radioimmunoassay.

Authors:  S W Hall; J E Strong; A Broughton; M L Frazier; R S Benjamin
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP.

Authors:  M A DeBenedette; N R Chu; K E Pollok; J Hurtado; W F Wade; B S Kwon; T H Watts
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  6 in total

1.  Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity.

Authors:  Young H Kim; Beom K Choi; Kwang H Kim; Sang W Kang; Byoung S Kwon
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

2.  Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant.

Authors:  Jung D Kim; Chang H Kim; Byoung S Kwon
Journal:  Mol Cells       Date:  2011-01-11       Impact factor: 5.034

Review 3.  Dual immunoregulatory pathways of 4-1BB signaling.

Authors:  Dass S Vinay; Kiweon Cha; Byoung S Kwon
Journal:  J Mol Med (Berl)       Date:  2006-08-05       Impact factor: 4.599

4.  Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.

Authors:  Wei Lin; Caroline J Voskens; Xiaoyu Zhang; Daniel G Schindler; Aaron Wood; Erin Burch; Yadong Wei; Lieping Chen; Guoliang Tian; Koji Tamada; Lai-Xi Wang; Dan H Schulze; Dean Mann; Scott E Strome
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

Review 5.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

Review 6.  4-1BB: A promising target for cancer immunotherapy.

Authors:  Alyssa Min Jung Kim; Macy Rose Nemeth; Seung-Oe Lim
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.